The global brain tumor diagnosis and therapeutics market size is expected to reach USD 4.94 billion by 2030, registering a CAGR of 7.1% during the forecast period. The market is expected to pose lucrative growth over the forecast period, owing to the increasing incidence of various brain cancers, particularly glioblastoma, coupled with the rising geriatric population.
Increasing Public-Private Partnerships (PPPs) in the health sector, which are modernizing diagnostic imaging and radiology services, are supporting the expansion of this industry. Emerging technologies like Sodium Magnetic Resonance Imaging(23Na MRI), Positron Emission Tomography (PET), and Chemical Exchange Saturation Transfer (CEST) are used to detect the response of brain tumors in multicenter clinical trial settings. In addition, these technologies are helpful in quantitatively imaging tumor response to therapies, thereby promoting their use during treatment.
These technologies have the potential to extend MRI beyond anatomical imaging by providing information on physiology and cellular metabolism, thereby increasing the efficiency of diagnosis. Hence, the market is expected to witness productive growth over the forecast period.
Moreover, ongoing research in molecular diagnostics to understand cell biology at the cellular level of malignancy and identification of gene mutations associated with malignancy is anticipated to significantly contribute toward the growth of the industry.
On the other hand, the high cost of diagnosing brain tumors, which ranges from USD 450 to 12,200, is likely to hinder the growth of the global brain tumor diagnosis market.
This product will be delivered within 2 business days.
Increasing Public-Private Partnerships (PPPs) in the health sector, which are modernizing diagnostic imaging and radiology services, are supporting the expansion of this industry. Emerging technologies like Sodium Magnetic Resonance Imaging(23Na MRI), Positron Emission Tomography (PET), and Chemical Exchange Saturation Transfer (CEST) are used to detect the response of brain tumors in multicenter clinical trial settings. In addition, these technologies are helpful in quantitatively imaging tumor response to therapies, thereby promoting their use during treatment.
These technologies have the potential to extend MRI beyond anatomical imaging by providing information on physiology and cellular metabolism, thereby increasing the efficiency of diagnosis. Hence, the market is expected to witness productive growth over the forecast period.
Moreover, ongoing research in molecular diagnostics to understand cell biology at the cellular level of malignancy and identification of gene mutations associated with malignancy is anticipated to significantly contribute toward the growth of the industry.
On the other hand, the high cost of diagnosing brain tumors, which ranges from USD 450 to 12,200, is likely to hinder the growth of the global brain tumor diagnosis market.
Brain Tumor Diagnosis And Therapeutics Market Report Highlights
- CT scan segment dominated the market with a revenue share of 25.6% in 2023 and is also likely to grow at a significant rate during the forecast period
- Targeted therapy segment drives market growth through its improved efficiency, reduced side effects, resistance mitigation capabilities, and advances in molecular profiling techniques, and expected to register a CAGR of 7.7% in the forecast period.
- North America is expected to dominate the brain tumor diagnosis and therapeutics market, owing to developed healthcare infrastructure coupled with rising awareness regarding advanced technologies amongst the population in this region. In addition, increasing consumer disposable income supported by healthcare insurance and reimbursement policies in the U.S. is expected to spur growth.
The leading players in the Brain Tumor Diagnosis and Therapeutics market include:
- Amgen Inc.
- AstraZeneca
- Bayer AG
- GE HealthCare
- F. Hoffmann-La Roche Ltd
- Eisai Co., Ltd
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Shimadzu Corporation
- Siemens Healthineers AG
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Brain Tumor Diagnosis And Therapeutics Market Variables, Trends, & Scope
Chapter 4. Brain Tumor Diagnosis And Therapeutics Market: Type Estimates & Trend Analysis
Chapter 5. Brain Tumor Diagnosis And Therapeutics Market: Product Estimates & Trend Analysis
Chapter 6. Brain Tumor Diagnosis and Therapeutics Market: Diagnosis Estimates & Trend Analysis
Chapter 7. Brain Tumor Diagnosis and Therapeutics Market: Therapeutics Estimates & Trend Analysis
Chapter 8. Brain Tumor Diagnosis and Therapeutics Market: End Use Estimates & Trend Analysis
Chapter 9. Brain Tumor Diagnosis and Therapeutics Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
Companies Mentioned
The leading players in the Brain Tumor Diagnosis and Therapeutics market include:- Amgen Inc.
- AstraZeneca
- Bayer AG
- GE HealthCare
- F. Hoffmann-La Roche Ltd
- Eisai Co., Ltd
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Shimadzu Corporation
- Siemens Healthineers AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 3.11 Billion |
| Forecasted Market Value ( USD | $ 4.94 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
